Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy

Dickson, Natalie R; Beauchamp, Karen D; Perry, Toni S; Roush, Ashley; Goldschmidt, Deborah; Edwards, Marie Louise; Blakely, L Johnetta

doi:10.1186/s41687-024-00700-4

Journal of Patient-Reported Outcomes

Table 3 Multivariable fitted cox proportional hazards model for dot

From: Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy

Cohort comparison	Regimen	Variate	HR (95% CI)	P value
ePRO vs HC^a	First IO	Cohort (ePRO vs HC)	0.83 (0.71–0.97)	< 0.05
		Age at index date (years)	1.00 (0.99–1.01)	0.781
		Male vs female	1.06 (0.91–1.24)	0.428
		White vs non-White	1.15 (0.90–1.48)	0.259
		Index cancer vs melanoma^b
		NSCLC	1.37 (1.07–1.76)	< 0.05
		Other	1.85 (1.41–2.44)	< 0.001
		Stage of index cancer at diagnosis vs stage I
		Stage II	0.92 (0.64–1.33)	0.668
		Stage III	0.71 (0.52–0.97)	< 0.05
		Stage IV	0.92 (0.69–1.24)	0.587
		Unknown	1.02 (0.68–1.51)	0.942
ePRO vs HC^a	Second	Cohort (ePRO vs HC)	0.89 (0.50–1.58)	0.685
		Age at index date (years)	0.99 (0.96–1.02)	0.646
		Male vs female	1.29 (0.69–2.41)	0.433
		White vs non-White	0.69 (0.29–1.64)	0.400
		Index cancer vs melanoma^b
		NSCLC	2.75 (0.93–8.11)	0.067
		Other	2.11 (0.66–6.74)	0.206
		Stage of index cancer at diagnosis vs stage I
		Stage II	0.72 (0.20–2.62)	0.617
		Stage III	0.47 (0.14–1.58)	0.223
		Stage IV	0.46 (0.15–1.42)	0.180
		Unknown	0.43 (0.09–2.08)	0.293
ePRO users vs non-users^a	First IO	Cohort (ePRO users vs non-users)	1.00 (0.81–1.23)	0.973
		Age at index date (years)	1.00 (0.99–1.01)	0.715
		Male vs female	0.95 (0.78–1.16)	0.628
		White vs non-White	1.19 (0.87–1.63)	0.277
		Insurance type (RSC vs non-RSC)	1.02 (0.83–1.25)	0.878
		Index cancer vs melanoma^b
		NSCLC	1.27 (0.91–1.77)	0.159
		Other	1.67 (1.16–2.41)	<0.01
		Stage of index cancer at diagnosis vs stage I
		Stage II	0.83 (0.52–1.33)	0.442
		Stage III	0.61 (0.42–0.90)	<0.05
		Stage IV	0.92 (0.65–1.32)	0.666
		Unknown	0.99 (0.60–1.63)	0.982
ePRO users vs non-users^a	Second	Cohort (ePRO users vs non-users)	0.30 (0.09–0.94)	< 0.05
		Age at index date (years)	0.99 (0.94–1.05)	0.811
		Male vs female	1.04 (0.38–2.84)	0.941
		White vs non-White	1.00 (0.20–5.00)	1.000
		Insurance type (RSC vs non-RSC)	1.49 (0.49–4.49)	0.481
		Index cancer vs melanoma^b
		NSCLC	5.87 (0.72–47.64)	0.097
		Other	3.91 (0.47–32.59)	0.207
		Stage of index cancer at diagnosis vs stage I
		Stage II	1.21 (0.15–9.41)	0.858
		Stage III	0.34 (0.07–1.64)	0.177
		Stage IV	0.39 (0.09–1.68)	0.205
		Unknown	0.24 (0.02–2.95)	0.266
Monotherapy vs combination therapy	First IO	Regimen (monotherapy vs combination therapy)	0.99 (0.84–1.18)	0.932
		Age at index date (years)	1.00 (0.99–1.01)	0.682
		Male vs female	1.06 (0.91–1.24)	0.448
		White vs non-White	1.15 (0.90–1.47)	0.267
		Insurance type (RSC vs non-RSC)	1.04 (0.89–1.22)	0.630
		Index cancer vs melanoma^b
		NSCLC	1.37 (1.07–1.76)	< 0.05
		Other	1.84 (1.40–2.42)	< 0.001
		Index year (n [%]) vs 2017
		2018	1.19 (0.87–1.63)	0.281
		2019	0.85 (0.66–1.08)	0.182
		2020	0.86 (0.72–1.03)	0.103
		Stage of index cancer at diagnosis vs stage I
		Stage II	0.91 (0.63–1.31)	0.623
		Stage III	0.71 (0.52–0.97)	< 0.05
		Stage IV	0.92 (0.69–1.23)	0.576
		Unknown	1.02 (0.69–1.53)	0.905

^aThe proportional hazards assumption does not hold for the univariable and multivariable regressions, and results should be interpreted with caution
^bMelanoma was selected as the reference by the analysis software (first tumor when listed alphabetically)
CI confidence interval; DoT duration of therapy; ePRO electronic patient-reported outcome; HC historical control; HR hazard ratio; IO immuno-oncology; NSCLC non-small cell lung cancer; RSC risk-share contract

Back to article page